Cargando…

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parakh, Sagun, Nicolazzo, Joseph, Scott, Andrew M, Gan, Hui Kong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678283/ https://www.ncbi.nlm.nih.gov/pubmed/34926242 http://dx.doi.org/10.3389/fonc.2021.718590

Ejemplares similares

Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
por: Balasubramanian, Adithya, et al.
Publicado: (2020)

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
por: Chia, Puey-Ling, et al.
Publicado: (2020)

Radiolabeled Antibodies for Cancer Imaging and Therapy
por: Parakh, Sagun, et al.
Publicado: (2022)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
por: Gan, Hui K, et al.
Publicado: (2021)

Antibody-drug conjugates: the clinical development in gastric cancer
por: Zhu, Yingze, et al.
Publicado: (2023)

Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022)

Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
por: Fenton, Sarah E., et al.
Publicado: (2023)

Antibody-drug conjugates: Present and future
por: Beck, Alain, et al.
Publicado: (2013)

A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
por: Jin, Yangbing, et al.
Publicado: (2021)

Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives
por: Raucher, Drazen, et al.
Publicado: (2018)

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis
por: Yao, Peizhuo, et al.
Publicado: (2023)

A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma
por: Rather, Gulam M., et al.
Publicado: (2019)

Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism?
por: Marcucci, Fabrizio, et al.
Publicado: (2019)

Current Options and Future Directions in Immune Therapy for Glioblastoma
por: Lynes, John, et al.
Publicado: (2018)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma
por: Kong, Benjamin Y, et al.
Publicado: (2022)

Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma
por: Harder, Bryan G., et al.
Publicado: (2018)

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
por: Wang, Yaning, et al.
Publicado: (2021)

Targeted therapies for renal cell carcinoma: more gains from using them again
por: Gan, H.K., et al.
Publicado: (2009)

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
por: Hegi-Johnson, Fiona, et al.
Publicado: (2022)

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
por: Mark, Cynthia, et al.
Publicado: (2023)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Drug Conjugates for Targeting Eph Receptors in Glioblastoma
por: Sharma, Puja, et al.
Publicado: (2020)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

Factors Affecting the Pharmacology of Antibody–Drug Conjugates
por: Lucas, Andrew T., et al.
Publicado: (2018)

Conjugation of ampicillin and enrofloxacin residues with bovine serum albumin and raising of polyclonal antibodies against them
por: Kumar, B. Sampath, et al.
Publicado: (2016)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
por: Chiang, Ming-Fu, et al.
Publicado: (2013)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

FUTURE-GB: functional and ultrasound-guided resection of glioblastoma – a two-stage randomised control trial
por: Plaha, Puneet, et al.
Publicado: (2022)

Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
por: Schürch, Christian M.
Publicado: (2018)

Antibody Conjugates-Recent Advances and Future Innovations
por: Leung, Donmienne, et al.
Publicado: (2020)

Editorial: Epigenetics and cellular plasticity in glioblastoma
por: Lo, Hui-Wen, et al.
Publicado: (2023)

Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy
por: Patrizii, Michele, et al.
Publicado: (2018)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_an6nso2a4lmbf9ksg0nrkr32g9